5 results on '"Homstad, Alison"'
Search Results
2. Rare variants in tenascin genes in a cohort of children with primary vesicoureteric reflux
- Author
-
Elahi, Shan, Homstad, Alison, Vaidya, Himani, Stout, Jennifer, Hall, Gentzon, Wu, Guanghong, Conlon, Peter, Routh, Jonathan C., Wiener, John S., Ross, Sherry S., Nagaraj, Shashi, Wigfall, Delbert, Foreman, John, Adeyemo, Adebowale, Gupta, Indra R., Brophy, Patrick D., Rabinovich, C. Egla, and Gbadegesin, Rasheed A.
- Subjects
Bladder diseases -- Research -- Risk factors -- Development and progression -- Care and treatment ,Chronic kidney failure -- Research -- Risk factors ,Health - Abstract
Background Primary vesicoureteral reflux (PVUR) is the most common malformation of the kidney and urinary tract, and reflux nephropathy is a major cause of chronic kidney disease in children. Recently, we reported mutations in the tenascin XB gene (TNXB) as a cause of PVUR with joint hypermobility. Methods To define the role of rare variants in tenascin genes in the etiology of PVUR, we screened a cohort of patients with familial PVUR (FPVUR) and non-familial PVUR (NFPVUR) for rare missense variants inTNXB and the tenascin C gene (TNC) after excluding mutations in ROBO2 and SOX17. Results The screening procedure identified 134 individuals from 112 families with PVUR; two families with mutations in ROBO2 were excluded from further analysis. Rare missense variants in TNXB were found in the remaining 110 families, of which 5/55 (9 %) families had FPVUR and 2/55 (4 %) had NFPVUR. There were no differences in high-grade reflux or renal parenchymal scarring between patients with and without TNXB variants. All patients with TNXB rare variants who were tested exhibited joint hypermobility. Overall we were able to identify causes of FPVUR in 7/57 (12 %) families (9 % in TNXB and 3 % in ROBO2). Conclusions In conclusion, the identification of a rare missense variant in TNXB in combination with a positive family history of VUR and joint hypermobility may represent a non-invasive method to diagnose PVUR and warrants further evaluation in other cohorts., Author(s): Shan Elahi[sup.1] , Alison Homstad[sup.1] [sup.2] , Himani Vaidya[sup.1] [sup.2] , Jennifer Stout[sup.1] , Gentzon Hall[sup.2] [sup.3] , Guanghong Wu[sup.2] [sup.3] , Peter Conlon[sup.1] , Jonathan C. Routh[sup.1] [sup.4] [...]
- Published
- 2016
- Full Text
- View/download PDF
3. Phosphodiesterase 5 inhibition ameliorates angiontensin II-induced podocyte dysmotility via the protein kinase G-mediated downregulation of TRPC6 activity.
- Author
-
Hall, Gentzon, Rowell, Janelle, Farinelli, Federica, Gbadegesin, Rasheed A., Lavin, Peter, Guanghong Wu, Homstad, Alison, Malone, Andrew, Lindsey, Thomas, Jiang, Ruiji, Spurney, Robert, Tomaselli, Gordon F., Kass, David A., and Winn, Michelle P.
- Subjects
PHOSPHODIESTERASE-5 inhibitors ,KIDNEY disease treatments ,CGMP-dependent protein kinase ,TRP channels ,CALCINEURIN - Abstract
The emerging role of the transient receptor potential cation channel isotype 6 (TRPC6) as a central contributor to various pathological processes affecting podocytes has generated interest in the development of therapeutics to modulate its function. Recent insights into the regulation of TRPC6 have revealed PKG as a potent negative modulator of TRPC6 conductance and associated signaling via its phosphorylation at two highly conserved amino acid residues: Thr
69 /Thr70 (Thr69 in mice and Thr70 in humans) and Ser321 /Ser322 (Ser321 in mice and Ser322 in humans). Here, we tested the role of PKG in modulating TRPC6-dependent responses in primary and conditionally immortalized mouse podocytes. TRPC6 was phosphorylated at Thr69 in nonstimulated podocytes, but this declined upon ANG II stimulation or overexpression of constitutively active calcineurin phosphatase. ANG II induced podocyte motility in an in vitro wound assay, and this was reduced 30-60% in cells overexpressing a phosphomimetic mutant TRPC6 (TRPC6T70E/S322E ) or activated PKG (P < 0.05). Pretreatment of podocytes with the PKG agonists S-nitroso-N-acetyl-DL-penicillamine (nitric oxide donor), 8-bromo-cGMP, Bay 41-2772 (soluble guanylate cyclase activator), or phosphodiesterase 5 (PDE5) inhibitor 4-{[3=,4=-(methylenedioxy) benzyl]amino}[7]-6-methoxyquinazoline attenuated ANG II-induced Thr69 dephosphorylation and also inhibited TRPC6-dependent podocyte motility by 30-60%. These data reveal that PKG activation strategies, including PDE5 inhibition, ameliorate ANG II-induced podocyte dysmotility by targeting TRPC6 in podocytes, highlighting the potential therapeutic utility of these approaches to treat hyperactive TRPC6-dependent glomerular disease. [ABSTRACT FROM AUTHOR]- Published
- 2014
- Full Text
- View/download PDF
4. Rare hereditary COL4A3/COL4A4 variants may be mistaken for familial focal segmental glomerulosclerosis.
- Author
-
Malone, Andrew F, Phelan, Paul J, Hall, Gentzon, Cetincelik, Umran, Homstad, Alison, Alonso, Andrea S, Jiang, Ruiji, Lindsey, Thomas B, Wu, Guanghong, Sparks, Matthew A, Smith, Stephen R, Webb, Nicholas J A, Kalra, Philip A, Adeyemo, Adebowale A, Shaw, Andrey S, Conlon, Peter J, Jennette, J Charles, Howell, David N, Winn, Michelle P, and Gbadegesin, Rasheed A
- Subjects
- *
KIDNEY glomerulus diseases , *HEMATURIA , *PROTEINURIA , *GENETIC disorders , *GENES - Abstract
Focal segmental glomerulosclerosis (FSGS) is a histological lesion with many causes, including inherited genetic defects, with significant proteinuria being the predominant clinical finding at presentation. Mutations in COL4A3 and COL4A4 are known to cause Alport syndrome (AS), thin basement membrane nephropathy, and to result in pathognomonic glomerular basement membrane (GBM) findings. Secondary FSGS is known to develop in classic AS at later stages of the disease. Here, we present seven families with rare or novel variants in COL4A3 or COL4A4 (six with single and one with two heterozygous variants) from a cohort of 70 families with a diagnosis of hereditary FSGS. The predominant clinical finding at diagnosis was proteinuria associated with hematuria. In all seven families, there were individuals with nephrotic-range proteinuria with histologic features of FSGS by light microscopy. In one family, electron microscopy showed thin GBM, but four other families had variable findings inconsistent with classical Alport nephritis. There was no recurrence of disease after kidney transplantation. Families with COL4A3 and COL4A4 variants that segregated with disease represent 10% of our cohort. Thus, COL4A3 and COL4A4 variants should be considered in the interpretation of next-generation sequencing data from such patients. Furthermore, this study illustrates the power of molecular genetic diagnostics in the clarification of renal phenotypes. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
5. Inverted formin 2 mutations with variable expression in patients with sporadic and hereditary focal and segmental glomerulosclerosis.
- Author
-
Gbadegesin, Rasheed A, Lavin, Peter J, Hall, Gentzon, Bartkowiak, Bartlomiej, Homstad, Alison, Jiang, Ruiji, Wu, Guanghong, Byrd, Alison, Lynn, Kelvin, Wolfish, Norman, Ottati, Carolina, Stevens, Paul, Howell, David, Conlon, Peter, and Winn, Michelle P
- Subjects
- *
KIDNEY diseases , *MOLECULAR genetics , *GENETIC testing , *CHRONIC kidney failure , *GLOMERULOSCLEROSIS - Abstract
Focal and segmental glomerulosclerosis (FSGS) is a major cause of end-stage kidney disease. Recent advances in molecular genetics show that defects in the podocyte play a major role in its pathogenesis and mutations in inverted formin 2 (INF2) cause autosomal dominant FSGS. In order to delineate the role of INF2 mutations in familial and sporadic FSGS, we sought to identify variants in a large cohort of patients with FSGS. A secondary objective was to define an approach for genetic screening in families with autosomal dominant disease. A total of 248 individuals were identified with FSGS, of whom 31 had idiopathic disease. The remaining patients clustered into 64 families encompassing 15 from autosomal recessive and 49 from autosomal dominant kindreds. There were missense mutations in 8 of the 49 families with autosomal dominant disease. Three of the detected variants were novel and all mutations were confined to exon 4 of INF2, a regulatory region responsible for 90% of all changes reported in FSGS due to INF2 mutations. Thus, in our series, INF2 mutations were responsible for 16% of all cases of autosomal dominant FSGS, with these mutations clustered in exon 4. Hence, screening for these mutations may represent a rapid, non-invasive and cost-effective method for the diagnosis of autosomal dominant FSGS. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.